Orthocell Posts Record U.S. Monthly Sales for Remplir Nerve Wrap
Australian medtech Orthocell sold 92 units of its Remplir collagen nerve wrap in October 2026, marking the strongest U.S. month since the product launched.
Orthocell Ltd recorded its highest single-month U.S. sales figure for its Remplir nerve wrap device in October 2026, moving 92 units and signaling growing commercial traction for the Australian medical technology firm in one of the world's most competitive healthcare markets.
Remplir is an FDA-cleared collagen nerve wrap engineered to support the repair and protection of peripheral nerves. Designed and manufactured in Australia, the device is positioned by the company as an emerging category leader across key international markets where peripheral nerve injury treatment remains a significant clinical need.
Read more Cognizant Deploys 25,000 Staff to Scale OpenAI Solutions for Enterprise Clients →
The October milestone represents a notable inflection point for Orthocell's U.S. commercial strategy. Peripheral nerve repair is a specialized surgical segment, and building consistent monthly volume in the American market typically requires sustained engagement with hospital systems, surgical specialists, and procurement networks — making the record result a meaningful operational signal beyond a single data point.
Orthocell's progress with Remplir reflects a broader pattern among Australian medtech companies seeking to scale FDA-cleared devices into the lucrative U.S. market, where reimbursement pathways and clinical adoption cycles can determine whether a product achieves sustained revenue growth or stalls after initial approval.
Continue reading at All Financial Services & Investing.
